These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 18528730)
1. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Beasley GM; Petersen RP; Yoo J; McMahon N; Aloia T; Petros W; Sanders G; Cheng TY; Pruitt SK; Seigler H; Tyler DS Ann Surg Oncol; 2008 Aug; 15(8):2195-205. PubMed ID: 18528730 [TBL] [Abstract][Full Text] [Related]
2. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821 [TBL] [Abstract][Full Text] [Related]
3. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289 [TBL] [Abstract][Full Text] [Related]
4. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Kroon HM; Moncrieff M; Kam PC; Thompson JF Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571 [TBL] [Abstract][Full Text] [Related]
6. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498 [TBL] [Abstract][Full Text] [Related]
7. Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Moncrieff MD; Kroon HM; Kam PC; Stalley PD; Scolyer RA; Thompson JF Ann Surg Oncol; 2008 Oct; 15(10):2749-56. PubMed ID: 18648882 [TBL] [Abstract][Full Text] [Related]
8. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
10. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288 [TBL] [Abstract][Full Text] [Related]
11. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Brady MS; Brown K; Patel A; Fisher C; Marx W Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448 [TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. Sharma K; Beasley G; Turley R; Raymond AK; Broadwater G; Peterson B; Mosca P; Tyler D Ann Surg Oncol; 2012 Aug; 19(8):2563-71. PubMed ID: 22476748 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Boesch CE; Meyer T; Waschke L; Merkel S; Goehl J; Hohenberger W; Knorr C Int J Hyperthermia; 2010 Feb; 26(1):16-20. PubMed ID: 20100048 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Kroon HM; Lin DY; Kam PC; Thompson JF Ann Surg; 2009 Jun; 249(6):1008-13. PubMed ID: 19474677 [TBL] [Abstract][Full Text] [Related]
15. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Möller MG; Lewis JM; Dessureault S; Zager JS Int J Hyperthermia; 2008 May; 24(3):275-89. PubMed ID: 18393005 [TBL] [Abstract][Full Text] [Related]
16. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Brady MS; Brown K; Patel A; Fisher C; Marx W Melanoma Res; 2009 Apr; 19(2):106-11. PubMed ID: 19282789 [TBL] [Abstract][Full Text] [Related]
17. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771 [TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion for unresectable melanoma of the extremities. Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572 [TBL] [Abstract][Full Text] [Related]
19. Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Kam PC; Thompson JF Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1039-45. PubMed ID: 20604735 [TBL] [Abstract][Full Text] [Related]
20. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]